Health

What Zepbound's FDA Approval for Sleep Apnea Means

The FDA approved Zepbound on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. Trial results, risks, and who it is for.

February 07, 2026 2 min read
What Zepbound's FDA Approval for Sleep Apnea Means

On December 20, 2024, the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. It is used with a reduced-calorie diet and more physical activity, and it carries a boxed warning about thyroid tumors seen in rats.


What the Trials Showed

The approval rested on two randomized, placebo-controlled trials of 469 adults without type 2 diabetes. Participants took 10 or 15 mg of tirzepatide weekly or a placebo for 52 weeks. Breathing events per hour (the AHI) fell by about 51% and 59% on tirzepatide versus about 3% on placebo, and participants lost an average of 17.7% and 19.6% of their body weight. Eli Lilly funded the trials.

Sleep Apnea’s Hidden Weight Connection

Sleep apnea can affect anyone, but it is more common in people who have overweight or obesity. Excess tissue around the neck and throat can narrow the airway and make it more likely to collapse during sleep. In a Wisconsin cohort, a 10% weight loss predicted a 26% decrease in the AHI.

Where CPAP Falls Short

CPAP therapy works when used. It keeps airways open and reduces snoring and daytime sleepiness. The SAVE trial found that adding CPAP to usual care did not significantly reduce cardiovascular events in adults with sleep apnea and heart or brain blood vessel disease. A 2016 review of 82 studies put the overall CPAP non-adherence rate at 34.1%.

Safety

Zepbound carries a boxed warning. In rats, tirzepatide caused thyroid C-cell tumors, and it is unknown whether it does in humans. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Common side effects are digestive, including nausea and diarrhea. The approval applies to adults with obesity and moderate-to-severe sleep apnea. The trials lasted 52 weeks, so long-term use is not answered by this data.

Newsletter

Get next week's issue in your inbox

Unsubscribe anytime · Privacy

Want more details? Read the complete article.

Read Full Article

Connected ideas

The same ideas, across different fields.

See how this connects →

Newsletter

Unsubscribe anytime · Privacy